Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Supernus (SUPN) Stock Price & Analysis

0 Followers

SUPN Stock Chart & Stats

MX$645.80MX$0.00(0.00%)
At close:
No data to display
Day’s Range
MXN 645.80 - MXN 645.80
52-Week Range
MXN 645.80 - MXN 645.80
Previous Close
MXN 645.80
Volume
N/A
Average Volume (3M)
0
Market Cap
MXN 100.95B
Enterprise Value
MXN 4.57B
Total Cash (Recent Filing)
MXN 305.00M
Total Debt (Recent Filing)
MXN 501.00M
Price to Earnings (P/E)
9.9
Beta
0.13
Next Earnings
Mar 04, 2027 (Est.)
EPS Estimate
17.35
Next Dividend Ex-Date
N/A
Dividend Yield
28.88%

Bulls Say, Bears Say

Bulls Say

SUBLOCADE Growth And Profitability

SUBLOCADE is showing strong commercial momentum alongside expanding profitability, supporting durable earnings growth rather than relying solely on cost reduction. Continued patient adoption and higher margins can strengthen internal cash generation and fund investment across Indivior’s broader addiction-treatment portfolio.

Broader CNS Platform And Synergies

Combining Indivior with Supernus broadens the commercial portfolio across addiction, psychiatry and neurology while adding meaningful scale. The planned cost synergies should improve operating leverage and create a larger platform for product launches, business development and sustained reinvestment.

SUBLOCADE Competitive Durability

High market share and extensive patent protection provide SUBLOCADE with important commercial and intellectual-property defenses. This supports revenue durability over the medium term, while manufacturing complexity and additional patent applications may make near-term generic erosion less likely.

Bears Say

Negative Shareholders’ Equity

Negative equity is a structural balance-sheet weakness that makes leverage metrics less informative and reduces financial resilience. Combined with sizable debt, it leaves less flexibility to absorb weaker profitability or cash flow and could constrain capital allocation during business setbacks.

Volatile Cash Conversion

Inconsistent cash generation weakens confidence that reported earnings will translate into dependable funding for operations and investment. The sharp TTM free-cash-flow decline and prior negative periods could limit flexibility for debt reduction, product development or other strategic priorities.

Higher Post-merger Debt

The merger increases absolute indebtedness and introduces greater fixed financial obligations than the pre-deal structure. Although leverage is described as moderate, higher debt can reduce flexibility for future acquisitions, intensify sensitivity to weaker cash generation and compete with investment in growth products.

SUPN FAQ

What was Supernus’s price range in the past 12 months?
Supernus lowest stock price was Mex$645.80 and its highest was Mex$645.80 in the past 12 months.
What is Supernus’s market cap?
Supernus’s market cap is Mex$100.95B.
When is Supernus’s upcoming earnings report date?
Supernus’s next earnings report is estimated for Mar 04, 2027 (not yet confirmed), which is in 115 days.
How were Supernus’s earnings last quarter?
Supernus released its earnings results on Oct 29, 2026. The company reported Mex$24.494 earnings per share for the quarter, beating the consensus estimate of Mex$19.688 by Mex$4.806.
Is Supernus overvalued?
According to Wall Street analysts Supernus’s price is currently Undervalued.
Does Supernus pay dividends?
Supernus does not currently pay dividends.
What is Supernus’s EPS estimate?
Supernus’s EPS estimate is 17.35.
How many shares outstanding does Supernus have?
Supernus has 207,724,090 shares outstanding.
What happened to Supernus’s price movement after its last earnings report?
Supernus reported an EPS of Mex$24.494 in its last earnings report, beating expectations of Mex$19.688. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Supernus?
Hedge funds hold Supernus shares: hedge funds decreased their holdings by 1.0M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology